Qomel Co.’s board of directors approved nearly $1.38 million worth of an investment in Kure Cells, to be funded from its own internal resources
Qomel Co.’s board of directors approved, on Oct. 12, an investment in Kure Cells, a US company operating in biotechnology, cell therapies, and regenerative medicine, at a total value of nearly $1.38 million (SAR 5.18 million), according to a statement to Tadawul. The share price is $94, and the estimated post-closing ownership will be around 1.3% (a non-controlling stake). The investment will be funded from its own internal resources. 
This investment aligns Qomel’s strategic direction to invest in the development of advanced therapeutic products and technologies with growing demand and promising market prospects and is consistent with the company’s overall strategy.
It is worth noting that Kure Cells is a US company (incorporated under Delaware law following a re-incorporation). It is a leading biotechnology company focused on developing cell-based therapy technologies within regenerative medicine, with an emphasis on rapid-manufacturing platforms for CAR-T therapies and research-stage oncology programs.
No immediate material impact is anticipated, while any future impact—if any—will depend on the performance of the target company and the development of Qomel’s investment therein. Qomel will disclose any material developments in this regard as they arise.
There are no related parties involved in this investment, the statement added.
Qomel Co.’s board of directors approved nearly $1.38 million worth of an investment in Kure Cells, to be funded from its own internal resources
Qomel Co.’s board of directors approved, on Oct. 12, an investment in Kure Cells, a US company operating in biotechnology, cell therapies, and regenerative medicine, at a total value of nearly $1.38 million (SAR 5.18 million), according to a statement to Tadawul. The share price is $94, and the estimated post-closing ownership will be around 1.3% (a non-controlling stake). The investment will be funded from its own internal resources.
This investment aligns Qomel’s strategic direction to invest in the development of advanced therapeutic products and technologies with growing demand and promising market prospects and is consistent with the company’s overall strategy.
It is worth noting that Kure Cells is a US company (incorporated under Delaware law following a re-incorporation). It is a leading biotechnology company focused on developing cell-based therapy technologies within regenerative medicine, with an emphasis on rapid-manufacturing platforms for CAR-T therapies and research-stage oncology programs.
No immediate material impact is anticipated, while any future impact—if any—will depend on the performance of the target company and the development of Qomel’s investment therein. Qomel will disclose any material developments in this regard as they arise.
There are no related parties involved in this investment, the statement added.
